2021

​

Microdosing of the classic psychedelics in participants who were not previously microdosing yielded results suggesting improvements in well-being, depression, and anxiety scores (Kaertner et al., 2021).

​

A study on mice and rats found that LSD increased sociability and positive interaction with peers (De Gregorio et al., 2021).

​

2016-2020

​

A literature review concluded that there is significant evidence for, or great promise in, the use of LSD for alcoholism (in improving quality of life), neurotic disorders like anxiety and depression, heroin use disorder, and anxiety associated with life-threatening diseases (Fuentes et al., 2020).

​

The use of 5-MeO-DMT for recreational purposes was correlated with improvements in anxiety and depression scores in approximately 80% of participants (Davis et al., 2019).

​

A review found that across all types of psychedelics being studied, almost 4/5 participants experienced a clinically significant reduction in symptoms in all of the studied mental illnesses (Rucker et al., 2016).

​

Ayahuasca (a preparation containing DMT and a compound designed to make it last longer in the body and brain) was proposed to have numerous beneficial effects to mental health based on its pharmacology, which was examined in detail (Frecska et al., 2016).

​

A study and review of literature found that the use of DMT in the form of ayahuasca produced long-term or projected long-term positive effects on cognition and mental health with no notable negative side effects (Santos et al., 2016).

​

LSD was found to reduce the reliving of traumatic experiences, also called mental time travel, in patients being treated for trauma-related mental illness (Speth et al., 2016).

​

LSD therapy was found to produce the most clinically significant reduction of depressive symptoms compared to any available antidepressant medication in chronically depressed adults, with some experiencing a complete remission (i.e. complete elimination of symptoms) (Carhart-Harris et al., 2016).

​

Two studies on depression and anxiety found a decrease in associated psychological symptoms for six or more months in up to 60-80% of patients following a single dose of psilocybin (Griffiths et al., 2016; Ross et al., 2016).

​

2011-2015

​

DMT (prepared as ayahuasca) was found to reduce symptoms within four hours in patients with depression who had not responded to conventional medications, with effects still present at the 3-week follow-up. Note that this study was not placebo controlled (Frood, 2015).

​

A study involving chronically depressed patients suffering from life-threatening diseases demonstrated significant relief of all depressive symptoms in all patients for at least 12 months following LSD administration in a therapeutic setting (Gasser et al., 2015).

​

Psilocybin was found to be more effective than traditional treatments alone when treating patients for alcoholism (Bogenshutz, 2015).

​

A study on patients with life-threatening cancers showed a significant decrease in end-of-life related anxiety and depression for as long as six months after the administration of psilocybin (Advokat et al, 2019 referencing Griffiths, 2015).

​

A study on patients attempting to quit smoking revealed promising results when psilocybin was used as an adjunct to smoking-cessation therapy (Johnson et al., 2014).

​

A study of over nearly 22'000 individuals found negligible negative impacts to mental health as a result of the use of classic psychedelics and found that lasting positive mental health outcomes were the norm (Krebs et al., 2013).

​

The classic psychedelics were found to produce promising results in a study on its use in treating addictions, with the study concluding that further research would be necessary to confirm these findings (Bogenschutz, 2012).

​

A meta-analysis found that even a single dose of LSD in conjunction with alcoholism therapy produced significantly better outcomes for patients regarding alcohol misuse than therapy alone (Krebs et al., 2012).

​

A study involving MRIs on patients who had received doses of psilocybin found that their brains were much more capable of entering states of deep meditation, associated with positive mental health improvements (Carhart-Harris et al., 2012).

​

A study performed on terminal cancer patients found a clinically significant reduction in anxiety and depression associated with their condition following administration of psilocybin (Grob et al., 2011).

​

A review of existing literature found the risk of physiological harm due to psilocybin mushroom use to be negligible, with the risk of panic attacks (which can be mitigated by proper clinical conditions) being the only concern (van Amsterdam et al., 2011).

​

2000-2010

​

Psilocybin therapy found to produce profound reduction in OCD-related symptoms (23-100%) in all participants with no adverse effects (other than temporary increases in blood pressure without consequence in one patient) (Moreno et al., 2006)

​

​